Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.MicroDose Therapeutx has received Therapeutic Discovery Project grants totaling $977,917 from the US Internal Revenue Service (IRS) in support of four major programs it is currently progressing.
Subscribe to our email newsletter
The grants, which target therapeutic discovery projects that show a reasonable potential to result in new therapies to treat areas of unmet medical need or prevent or treat chronic or acute diseases, among other criteria, were awarded to MicroDose to support four internal projects, two of which are MDT-637 – Treatment of Respiratory Syncytial Virus (RSV) and MDT-006 – Treatment of Gastrointestinal Diseases.
MDT-637 is a clinical stage, anti-viral product that has been shown to effectively block RSV infection both in vitro and in animal models for RSV infection. MDT-637 acts by targeting the viral fusion protein, which is the only validated target for RSV treatments.
MDT-006, a novel, highly selective, non absorbed, small molecule, works by activating of the P2Y2 receptor which stimulates chloride ion secretion into the gastrointestinal tract, a clinically validated mechanism to increase fluid secretion and accelerate gastrointestinal motility.
MicroDose Therapeutx director of finance John Krall said that being selected against steep odds to receive these grants is an honor for the company, and the funds will enable it to move at a more rapid pace toward achieving its goals.